Pro-Inflammatory cytokines & neurobehavioral symptoms in breast cancer patients

促炎细胞因子

基本信息

批准号：
7740298
负责人：
Sunita K Patel
金额：
$ 18.26万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-01 至 2011-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7740298
关键词：
Acute Address Aftercare Behavioral Behavioral Symptoms Benign Biological Markers Breast Breast Carcinoma Cancer Patient Chronic Clinical Cognitive Cross-Sectional Studies Cytokine Network Pathway Diagnosis Diagnostic Neoplasm Staging Disease Employee Strikes Evaluation Fatigue Functional disorder Goals Immunologics Impaired cognition Individual Inflammatory Interleukin-1 Interleukin-6 Knowledge Late Effects Link Literature Local Therapy Long-Term Survivors Longitudinal Studies Malignant Neoplasms Measures Methods Neuraxis Neurocognitive Outcome Participant Patients Plasma Postmenopause Prevalence Proliferating Relative (related person)Reporting Research Risk Serum Stage at Diagnosis Survivors Symptoms TNF gene Time Woman Women&apos s Group Work abstracting anakinra cancer cell cancer therapy chemotherapy cognitive function comparison group cytokine disease characteristic disturbance in affect experience improved malignant breast neoplasm neurobehavioral patient population prognostic public health relevance receptor response survivorship tumor

项目摘要

DESCRIPTION (provided by applicant): Pro-inflammatory cytokines and neurobehavioral symptoms in women with breast cancer. Abstract Survivors of breast cancer report debilitating behavioral symptoms, such as fatigue and neurocognitive dysfunction, which are evident in some individuals even at pre-treatment baseline. There is sufficient evidence from varied lines of research to propose that cancer-related neurobehavioral symptoms may be driven, at least in part, by activation of the pro-inflammatory cytokine network. Concentrations of specific pro-inflammatory cytokines (IL-6, TNF) and soluble receptors in serum obtained prior to treatment in breast cancer patients are significantly higher than levels found in healthy individuals and have prognostic value; however, these pre- treatment elevations have not yet been evaluated with respect to their association with either acute or chronic behavioral symptoms. Among survivors of breast cancer, elevated levels of circulating sIL-6R and IL-1ra have emerged as prominent biomarkers of persistent fatigue in cross-sectional studies of women several years post chemotherapy. No similar work has identified biomarkers of neurocognitive dysfunction in this patient population, and it is not known if the cytokine links with fatigue, or other behavioral symptoms, exist closer to the diagnosis period or evolve over time as "late effects". In this study, we will address this knowledge gap as we will evaluate this association prior to cancer treatment, and again following treatment completion. We will compare these associations in a minimum of 137 breast cancer patients relative to two comparison groups at pre-treatment, and longitudinally evaluate only the breast cancer group after treatment. Findings are expected to increase our knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects. PUBLIC HEALTH RELEVANCE: Findings are expected to increase knowledge about the possible biomarkers associated with neurobehavioral symptoms in breast cancer patients, for the purpose of better identifying and treating those at risk for such effects.

描述（由申请人提供）：乳腺癌女性的促炎细胞因子和神经行为症状。乳腺癌的摘要幸存者报告说，行为症状使人衰弱，例如疲劳和神经认知功能障碍，即使在治疗前基线中，这些症状也很明显。有足够的研究有足够的证据，以提出至少部分通过激活促炎性细胞因子网络来驱动与癌症相关的神经行为症状。在乳腺癌患者接受治疗前获得的血清中特异性促炎细胞因子（IL-6，TNF）和可溶性受体的浓度显着高于健康个体的水平，并且具有预后价值。但是，这些预处理升高尚未与它们与急性或慢性行为症状的关联进行评估。在乳腺癌的幸存者中，在化学疗法几年后，在妇女的横断面研究中，循环SIL-6R和IL-1RA水平升高已成为持续疲劳的重要生物标志物。没有类似的工作确定该患者人群中神经认知功能障碍的生物标志物，并且尚不清楚细胞因子与疲劳或其他行为症状的联系是否更接近诊断期，还是随着时间的推移而演变为“晚期效应”。在这项研究中，我们将解决这一知识差距，因为我们将在癌症治疗之前和治疗完成后再次评估这种关联。我们将在预处理前的两个比较组中与至少137名乳腺癌患者进行比较，并在治疗后纵向评估乳腺癌组。预计发现将增加我们对乳腺癌患者中与神经行为症状相关的生物标志物的了解，以便更好地识别和治疗有这种影响风险的生物标志物。公共卫生相关性：预计发现将增加有关乳腺癌患者中与神经行为症状相关的可能生物标志物的知识，以便更好地识别和治疗有这种影响风险的人。